H.C. Wainwright lowered the firm’s price target on Crinetics to $33 from $35 and keeps a Buy rating on the shares post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- CRNX Upcoming Earnings Report: What to Expect?
- Crinetics to hold a KOL webinar
- Crinetics reports Q2 EPS (94c), consensus (86c)
- Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly